Recent Updates
Recently added Catalysts
EYPT Positive Sentiment Score: 75/100

Legal Disclaimers 2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995

Key Takeaway: EyePoint Pharmaceuticals, Inc. recently reported a positive EOP2 meeting with the FDA, where they agreed on key trial design elements for their product DURAVYU. The company is preparing to initiate the LUGANO trial in the second half of 2024, with the LUCIA trial to follow. Initial data shows no serious adverse events related to DURAVYU, and the reported adverse events were primarily mild. However, the company acknowledges that various risks may impact future outcomes and timelines.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive EOP2 meeting with FDA indicates regulatory support.
  • No reported DURAVYU-related ocular or systemic serious adverse events.
  • High percentage (97%) of adverse events reported were mild and expected.
  • On track to initiate key trials in the second half of 2024.

CONCERNS & RISKS

  • Future results and expectations are uncertain and depend on various risks.
  • Potential delays due to interim FDA Division of Ophthalmology leadership.
  • Risks associated with clinical trials could impact timelines and outcomes.
  • Dependence on external partners and compliance with complex regulations.

Full Press Release Details

Positive EOP2 meeting with FDA completed in April 2024; waiting for final FDA review* Key trial design elements agreed upon with FDA: Two pivotal, non-inferiority trials vs. aflibercept control 12-month primary efficacy endpoint (blended) basis of NDA submission DURAVYU re-dosing at six-month intervals 4 total doses Masking strategy We remain on-track to initiate the LUGANO trial (US) in 2H 2024 with LUCIA trial (US/OUS) to follow. *Timing TBD based on extenuating circumstances with the interim FDA Division of Ophthalmology leadership required for sign-off.
SAE, serious adverse event; AE, adverse event; IVT, intravitreal injection PRELIMINARY DATA CUT PENDING FINAL ANALYSIS 1- As of November 7, 2023 data cut 2- as deemed by the investigator No reported DURAVYU-related ocular or systemic SAEs Four ocular SAEs reported in a study eye none deemed DURAVYU related2 >97% of AEs reported were mild (Grade 1 or 2) and generally expected with IVT No insert migration into the anterior chamber No retinal occlusive vasculitis Low patient discontinuation rate of 4% up to week 32 No discontinuations were related to DURAVYU treatment 2024 EyePoint Pharmaceuticals, Inc.
Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made.
We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements.
Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission.
All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for DURAVYU in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including DURAVYU and EYP-2301; the potential for DURAVYU as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; and our longer term financial and business goals and expectations, are forward-looking statements.

Frequently Asked Questions

What was the outcome of the EOP2 meeting with the FDA in April 2024?

The EOP2 meeting with the FDA was positive, and key trial designs were agreed upon.

What trials are planned for the LUGANO and LUCIA studies?

The LUGANO trial in the US will start in the second half of 2024, followed by LUCIA.

What were the findings regarding serious adverse events related to DURAVYU?

No DURAVYU-related ocular or systemic serious adverse events were reported.

What is the patient discontinuation rate in the study?

The patient discontinuation rate was low at 4% up to week 32, unrelated to DURAVYU.

What are the primary endpoint details for DURAVYU trials?

The primary efficacy endpoint is a 12-month evaluation in two pivotal, non-inferiority trials.

Last updated: May 28, 2024